EN DE
Watch SoftOx Solutions AS for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SoftOx Solutions AS (SOFTX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SoftOx Solutions AS stock NOK 0.07, price NOK 0.10, that is 33.3% below the price, quality 53 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare NO · ISIN NO0010811961

SS SoftOx Solutions AS logo Thin data Nov 10, 2026

SoftOx Solutions AS

SOFTX · OL
Solid, but expensive

Our calculation puts a fair price 33% below what the stock costs today.

Low debt
Quality 53/100
Mixed Growth (revenue 5y +9.6 %/yr in NOK)
Revenue last quarter 56% below a year ago.
Fair value kr 0.0656 · Overvalued
Loss-making · -165.8% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch SoftOx Solutions AS for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 77.00 kr 0.0110 Fair Value kr 0.0656 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.0110 – kr 77.00 · fair‑value band kr 0.0492 – kr 0.0820 · the kr 0.0984 price screens above the kr 0.0656 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow SoftOx Solutions AS in your weekly email

Every Wednesday you see whether SoftOx Solutions AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections.

Show moreShow less

It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.

Stock analysis

SoftOx Solutions AS (SOFTX) currently trades at kr 0.0984, while our estimate is kr 0.0656, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.0492 (bear) to kr 0.0820 (bull), the price of kr 0.0984 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

SoftOx Solutions AS reported revenue of 15.6M NOK in FY2025 versus 7.9M NOK in FY2021, a compound +18.5%/yr. Reported net income was −10.8M NOK in FY2025.

Key figures

Market cap 269M NOK (≈ $28.3M) Micro · P/S ratio 21.3 · EPS (TTM) kr −0.0100 · Net margin −69.4% · Return on equity −34.4% · Return on assets (EBIT) −58.2% (5-year average) · Operating margin −447% · Revenue (TTM) 13.9M NOK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 80% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, SOFTX screens richer than that median.

Fair Value

Bear kr 0.0492 Fair Value kr 0.0656 Bull kr 0.0820
Price kr 0.0984 · Downside -33.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 97
Are margins and returns getting better?
Cashflow 46
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 79
Does it invest with discipline instead of growing at any price?
Low Volatility 39
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 55
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+96.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−522.0% (2020) → −73.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SOFTX screens overvalued: fair value 33% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SoftOx Solutions AS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Top 25%
Fair Value upside −33.3% · Below median
Profitability
Return on assets −31.9% · Below median
Net margin (12 months) −165.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −55.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 11.72× · Priciest 25%
P/S (12 months) 19.38× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SOFTX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SOFTX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SOFTX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SOFTX
argenx SE ARGX $971.55 $908.40 −7% vs SOFTX
CSL Limited CSL A$201.68 A$181.40 −10% vs SOFTX
Moderna, Inc MRNA $250.83 $158.70 −37% vs SOFTX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SOFTX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SOFTX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SOFTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SoftOx Solutions AS: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SoftOx Solutions AS Fair Value". https://www.fairvalue-calculator.com/stock/SOFTX

Frequently asked questions

Is SoftOx Solutions AS (SOFTX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.0656 versus a price of kr 0.0984, about 33% lower (overvalued).
What is the fair value of SOFTX?
Our estimate for SoftOx Solutions AS is kr 0.0656 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.0984.
What is the quality score of SOFTX?
SoftOx Solutions AS has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SoftOx Solutions AS (SOFTX)?
Our calculated price target is the estimate of kr 0.0656 (as of Nov 10, 2026). Cautious scenario kr 0.0492, optimistic scenario kr 0.0820. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SoftOx Solutions AS stock forecast for 2026?
Our estimate puts fair value at kr 0.0656, about 33% lower versus a price of kr 0.0984 (overvalued). Cautious scenario kr 0.0492, optimistic scenario kr 0.0820. The calculation is refreshed regularly with new filings.
What is the revenue of SoftOx Solutions AS (SOFTX)?
SoftOx Solutions AS reported trailing-twelve-month revenue of about 13.9M NOK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of SoftOx Solutions AS (SOFTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SoftOx Solutions AS it is kr 0.0656 per share (as of Nov 10, 2026), against a price of kr 0.0984.
Is SoftOx Solutions AS stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SOFTX trades above its calculated fair value: price kr 0.0984, fair value kr 0.0656, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOFTX?
No. The price is what the market pays today (kr 0.0984); the fair value is what the company's own numbers justify (kr 0.0656). For SoftOx Solutions AS the two are kr 0.0328 per share apart. That gap is exactly why we show both numbers side by side.
How much is SoftOx Solutions AS worth?
The market values SoftOx Solutions AS at about 269M NOK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.0984; our models calculate a fair value of kr 0.0656 per share.
What do the bullish and bearish scenarios say about SOFTX?
Our models span a range for SoftOx Solutions AS: cautious scenario kr 0.0492, base kr 0.0656, optimistic kr 0.0820 per share (as of Nov 10, 2026, price kr 0.0984). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SoftOx Solutions AS (SOFTX)?
Balance-sheet figures for SoftOx Solutions AS (as of Nov 10, 2026): return on equity −34.4%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is SOFTX from its 52-week high?
SoftOx Solutions AS trades at kr 0.0984, about 37% below its 52-week high of kr 0.1570 and 80% above the low of kr 0.0548 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0656 is for.
Which stocks are comparable to SoftOx Solutions AS?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SoftOx Solutions AS stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.0984, calculated fair value kr 0.0656 (−33%), Quality Score 53/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. SoftOx Solutions AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SoftOx Solutions AS (SOFTX)?
The closing price on Nov 10, 2026 was kr 0.0984. Our estimate is kr 0.0656, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SoftOx Solutions AS right now?
The price sits above even our optimistic bull case (kr 0.0820). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of SoftOx Solutions AS

How large is the market capitalisation of SoftOx Solutions AS (SOFTX)?
The market capitalisation of SoftOx Solutions AS is 269M NOK (≈ $28.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SoftOx Solutions AS (SOFTX)?
The price-to-sales ratio of SoftOx Solutions AS is 21.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SoftOx Solutions AS (SOFTX)?
Earnings per share at SoftOx Solutions AS are kr −0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SoftOx Solutions AS (SOFTX)?
The net margin of SoftOx Solutions AS is −69.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SoftOx Solutions AS (SOFTX)?
The return on equity (ROE) of SoftOx Solutions AS is −34.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SoftOx Solutions AS (SOFTX)?
On an EBIT basis the return on assets of SoftOx Solutions AS is −58.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SoftOx Solutions AS (SOFTX)?
The operating margin of SoftOx Solutions AS is −447% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SoftOx Solutions AS (SOFTX)?
Revenue at SoftOx Solutions AS is growing −55.6% versus a year earlier (3y avg +29.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SoftOx Solutions AS (SOFTX) generate?
The free cash flow of SoftOx Solutions AS is −18.9M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SoftOx Solutions AS (SOFTX) carry?
The net debt of SoftOx Solutions AS is 66.3M NOK (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SoftOx Solutions AS in the live analysis

One click puts SoftOx Solutions AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.